Clinical Trial Update: Post Marketing Surveillance of Nintedanib in Indian Patients With Idiopathic Pulmonary Fibrosis

View source ↗

Summary

This post-marketing surveillance study from Boehringer Ingelheim evaluates nintedanib in Indian patients with idiopathic pulmonary fibrosis, and results have be…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Idiopathic Pulmonary Fibrosis

Drugs mentioned

• Nintedanib (Ofev) (Nintedanib)

Snippet

Sponsor: Boehringer Ingelheim | Conditions: Idiopathic Pulmonary Fibrosis | Status: COMPLETED | Results posted: 2024-08-22